• Mediview XR

  Participated · Series A · Oct 2025

  MediView XR is a Cleveland-based med-tech company commercializing an augmented-reality ecosystem that fuses pre-operative CT data with live ultrasound to give clinicians ‘X-ray vision’ during interventions. Its FDA-cleared XR90 platform projects a 3D model of a patient’s internal anatomy directly onto the body, enabling head-up, hands-free guidance for biopsies, tumor ablations, injections, and other image-guided procedures. The system reduces physicians’ cognitive load by eliminating the need to translate 2D images into 3D mental maps and supports remote collaboration among care teams. MediView’s technology originated from Cleveland Clinic intellectual property and is positioned to become a new standard for less invasive care. With fresh capital, the company plans to accelerate commercial roll-out, expand industry partnerships, pursue additional regulatory approvals, and deepen AI-driven product development. Operational capacity will be scaled to meet increasing global demand. No revenue or user metrics were disclosed in the article.

• Method AI

  Participated · Series A · Aug 2025

  Method AI, led by CEO Doug Teany, is a Boston, MA-based medical technology company focused on improving oncology outcomes through image-guided surgical navigation. The company is developing a novel surgical ultrasound platform that visualizes anatomy deep below the visible surface of an organ and creates a 3D subsurface map for physicians. Its platform provides real-time guidance against an AI-generated surgical plan to assist procedures. Method AI aims to improve cancer-free survival rates for patients and has a stated potential to reduce over $1 billion in annual healthcare costs. The company raised $20M in Series A funding to support continued development of this surgical ultrasound platform.

• HealthPlan Data Solutions

  Participated · Equity · Apr 2025

  HealthPlan Data Solutions (HDS) provides pharmacy payment integrity, benefit optimization, and pharmacy claims analytics through its Claim Scan and Spotlight platforms. Claim Scan continuously monitors 100% of pharmacy claims in near real-time using more than 500 customizable/proprietary claim-scanning algorithms and AI, enabling detection and recovery of adjudication errors before they escalate. HDS says it has saved payers millions and protected more than 8 million covered lives by identifying overpayments to PBMs, eliminating contractual gray areas, and strengthening plan sponsor fiduciary oversight. The company emphasizes continuous oversight rather than retrospective, one-time audits, allowing customers to uncover trends, fix claim-level errors, and drive contract alignment. Near-term product plans include expanding the technology platform, developing more robust analytics, enhancing service capabilities, adding automated workflows, more Claim Scan algorithms, and ease-of-use improvements to deliver additional value and efficiency.

• orthobrain

  Participated · Equity · Apr 2025

  orthobrain provides a total orthodontic practice-growth system combining proprietary digital technology, AI-driven learning systems, and expert orthodontic mentorship to enable general practitioners to deliver orthodontic care. Its offerings include clinical workflow tools, educational resources through orthobrain University, and SimplyClear™, a proprietary clear aligner system launched in 2022 designed for dentists. The company is rolling out an enhanced technology platform to streamline clinical workflows and optimize treatment outcomes. Funding will support team expansion, technology enhancements, marketing, and educational initiatives to expand provider access. orthobrain reports strong commercial traction: revenue grew 145% year-over-year and doctor registrations surged more than 185% since 2023. The company emphasizes enabling case selection, treatment planning, and ongoing orthodontic guidance to drive practice profitability and patient retention. orthobrain is a dental practice growth system that integrates orthodontics into general practices using digital technology, proprietary AI, learning systems and the expertise of orthodontists. Founded in 2016 by Dr. Dan German and based in Cleveland, Ohio, the company positions itself as a proven integration platform for orthodontic services. In July 2022 orthobrain completed a $9M Series A financing. The company intends to use the funds to expand access to quality orthodontic care globally and to scale clinical and education support services. orthobrain also plans to invest in technological solutions and continue innovating its product and service offerings. The description of its core product emphasizes combining technology, AI and orthodontist expertise to drive practice growth.

• XII Medical

  Participated · Series B · Aug 2024

  XII Medical develops a patient-centric neuromodulation therapy to improve treatment and quality of life for people with obstructive sleep apnea. The company is clinical-stage and its platform is currently limited to investigational use and not available for sale. Led by CEO Garrett Schwab and founded in 2017, XII Medical is based in Union City, California. The company intends to use new funding to further product and clinical development. XII raised $45M in a recently announced financing to support those efforts. XII Medical is a private health technology company focused on treating obstructive sleep apnea (OSA). It is led by President and CEO Garrett Schwab and is based in Union City, California. The company is developing a proprietary, patient-centric solution for people suffering from OSA. XII Medical plans to use new funding to advance the development of that solution. The article does not disclose revenue, users, or other operating metrics. The company previously counted Cleveland Clinic as a founding investor.

No current team members are available.